All In Biotech

Drug Trial Radar · NCT03709927

4-way Crossover QT Evaluation in Healthy Subjects

A Phase 1, Randomized, Blinded, Placebo and Moxifloxacin Controlled, 4-Period Crossover, Study Evaluating the Effect of ZTI-01 on 12-Lead Electrocardiogram Parameters in Healthy Adult Subject

Last checked: Nov 19, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Jan 11, 2018

Primary completion

Apr 12, 2018

Study completion Aug 21, 2018

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
First posted
Oct 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if ZTI-01 (fosfomycin for injection), an investigational drug being developed to treat people with complicated urinary tract and kidney infections, has any effect on the electrical activity of the heart.

Conditions

  • Cardiac Repolarization in Healthy Subjects

Interventions

  • ZTI-01Drug

    6g IV fosfomycin

  • Moxifloxacin 400mgDrug

    oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)

  • Placebo IVOther

    IV Placebo (0.9% Normal Saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of ZTI-01 at the therapeutic and supra-therapeutic plasma concentration on cardiac repolarization expressed by QT intervalTime frame: 24 hour Holter ECG at Baseline (Day -1) & day of dosing (Day 1) in each of 4 periods. 10 replicates per time point at 13 timepoints: pre-dose: 60, 45 and 30 minutes; after the start of infusion: 0.5, 1 (end infusion), 1.25, 1.5, 2, 3, 4, 8, 12, & 24 hrs

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.